Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report
A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.
| 出版年: | Current Oncology |
|---|---|
| 主要な著者: | , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
MDPI AG
2021-06-01
|
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/1718-7729/28/3/199 |
| _version_ | 1850472296534245376 |
|---|---|
| author | Thierry Alcindor Sungmi Jung Lucy Gilbert |
| author_facet | Thierry Alcindor Sungmi Jung Lucy Gilbert |
| author_sort | Thierry Alcindor |
| collection | DOAJ |
| container_title | Current Oncology |
| description | A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment. |
| format | Article |
| id | doaj-art-3dc7dc4a7fdc48cfb47d01a18b4907fa |
| institution | Directory of Open Access Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| spelling | doaj-art-3dc7dc4a7fdc48cfb47d01a18b4907fa2025-08-19T22:40:42ZengMDPI AGCurrent Oncology1198-00521718-77292021-06-012832146214910.3390/curroncol28030199Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case ReportThierry Alcindor0Sungmi Jung1Lucy Gilbert2Cedars Cancer Center, Division of Medical Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, CanadaDepartment of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, CanadaCedars Cancer Center, Division of Gynecologic Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, CanadaA 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.https://www.mdpi.com/1718-7729/28/3/199adenosarcomasarcomaimmunotherapytargeted therapy |
| spellingShingle | Thierry Alcindor Sungmi Jung Lucy Gilbert Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report adenosarcoma sarcoma immunotherapy targeted therapy |
| title | Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report |
| title_full | Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report |
| title_fullStr | Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report |
| title_full_unstemmed | Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report |
| title_short | Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report |
| title_sort | clinical benefit from lenvatinib and pembrolizumab observed in mullerian adenosarcoma a case report |
| topic | adenosarcoma sarcoma immunotherapy targeted therapy |
| url | https://www.mdpi.com/1718-7729/28/3/199 |
| work_keys_str_mv | AT thierryalcindor clinicalbenefitfromlenvatinibandpembrolizumabobservedinmullerianadenosarcomaacasereport AT sungmijung clinicalbenefitfromlenvatinibandpembrolizumabobservedinmullerianadenosarcomaacasereport AT lucygilbert clinicalbenefitfromlenvatinibandpembrolizumabobservedinmullerianadenosarcomaacasereport |